Versartis, Inc. has announced it has raised $25 million in series C financing led by Aisling Capital.

Versartis, headquartered in Redwood City, Calif., is a biotechnology company developing therapeutics for patients with endocrine disorders.

Aisling Capital, headquartered in New York, is a private equity fund that invests in life science companies. It is a new investor in Versartis. Joining Aisling Capital in this round of funding were existing investors Index Ventures, New Leaf Venture Partners and Advent Venture Partners’ Advent Life Sciences fund. 

The primary use of the 25 million in series C financing will be to fund clinical trials of Versartis’s lead product, a once monthly form of recombinant human growth hormone.